Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03642132 · ClinicalTrials.gov registry record · Phase 3
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 79
- Enrollment target
NCT03642132 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 79 participants.
The verdict
NCT03642132, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 79 participants
- Enrollment target
Study Summary
JAVELIN Ovarian PARP 100 (B9991030) is an open-label, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV). On March 19, 2019, Sponsors alliance announced the discontinuation of the ongoing Phase III study, and the decision was based on several factors, including previous announced interim results from JAVELIN Ovarian 100 study (B9991010). Patients who remain in B9991030 study will continue receiving their randomized treatment assigned and will be monitored for appropriate safety assessments until treatment discontinuation.
Interventions
- DRUG Chemotherapy + avelumab followed by avelumab + talazoparib
- DRUG Chemotherapy followed by talazoparib maintenance
- DRUG Chemotherapy + bevacizumab followed by bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2021-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03642132
The ClinicalTrials.gov registry entry for NCT03642132 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Chemotherapy + avelumab followed by avelumab + talazoparib is the first listed.
NCT03642132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03642132 about?
NCT03642132 is a clinical study titled "Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)". JAVELIN Ovarian PARP 100 (B9991030) is an open-label, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib versus an active comparator in treatment-naïve patients with lo...
What is the current status of trial NCT03642132?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 79 participants. The study started on 2018-07-19. Estimated completion is 2021-12-22.
What interventions are being tested in trial NCT03642132?
The interventions under investigation include: Chemotherapy + avelumab followed by avelumab + talazoparib (DRUG), Chemotherapy followed by talazoparib maintenance (DRUG), Chemotherapy + bevacizumab followed by bevacizumab (DRUG).
Who is sponsoring clinical trial NCT03642132?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.